Verubecestat TFA

• CAT Number: I014753
• CAS Number: 2095432-65-6 (TFA)
• Molecular Formula: C19H18F5N5O5S
• Molecular Weight: 523.435
• Purity: ≥95%
• Target: Beta-Secretase Inhibitor
• Solubility: Soluble in DMSO, not in water
• InChI: InChI=1S/C17H17F2N5O3S.C2HF3O2/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14;3-2(4,5)1(6)7/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25);(H,6,7)/t17-;/m0./s1
• InChIKey: MNYVOIVLGITLBF-LMOVPXPDSA-N
• SMILES: O=C(NC1=CC=C(F)C([C@@](C2)(C)N=C(N)N(C)S2(=O)=O)=C1)C3=NC=C(F)C=C3.O=C(O)C(F)(F)F

Verubecestat TFA(CAT: I014753) is a trifluoroacetic acid salt form of Verubecestat. Verubecestat is a potent and selective inhibitor of beta-secretase 1 (BACE1), an enzyme involved in the production of amyloid-beta peptides, which are known to accumulate in the brains of individuals with Alzheimer’s disease. By inhibiting BACE1, Verubecestat TFA has the potential to reduce the production of amyloid-beta peptides and potentially slow down the progression of Alzheimer’s disease.

Reference

1: Thaisrivongs DA, Morris WJ, Tan L, Song ZJ, Lyons TW, Waldman JH, Naber JR, Chen W, Chen L, Zhang B, Yang J. A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931). Org Lett. 2018 Mar 16;20(6):1568-1571. doi: 10.1021/acs.orglett.8b00259. Epub 2018 Feb 26. PubMed PMID: 29481097.2: Chen W, Meng D, N’Zemba B, Morris WJ. Palladium-Catalyzed Enantioselective Synthesis of Cyclic Sulfamidates and Application to a Synthesis of Verubecestat. Org Lett. 2018 Mar 2;20(5):1265-1268. doi: 10.1021/acs.orglett.7b03639. Epub 2018 Feb 20. PubMed PMID: 29461065.3: Barhate CL, Lopez DA, Makarov AA, Bu X, Morris WJ, Lekhal A, Hartman R, Armstrong DW, Regalado EL. Macrocyclic glycopeptide chiral selectors bonded to core-shell particles enables enantiopurity analysis of the entire verubecestat synthetic route. J Chromatogr A. 2018 Mar 2;1539:87-92. doi: 10.1016/j.chroma.2018.01.042. Epub 2018 Jan 31. PubMed PMID: 29397980.4: Geerts H, Spiros A, Roberts P. Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model. Alzheimers Res Ther. 2018 Feb 2;10(1):14. doi: 10.1186/s13195-018-0343-5. PubMed PMID: 29394903; PubMed Central PMCID: PMC5797372.5: Villarreal S, Zhao F, Hyde LA, Holder D, Forest T, Sondey M, Chen X, Sur C, Parker EM, Kennedy ME. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage. J Alzheimers Dis. 2017;59(4):1393-1413. doi: 10.3233/JAD-170056. PubMed PMID: 28800329; PubMed Central PMCID: PMC5611839.6: Prati F, Bottegoni G, Bolognesi ML, Cavalli A. BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer’s Disease. J Med Chem. 2018 Feb 8;61(3):619-637. doi: 10.1021/acs.jmedchem.7b00393. Epub 2017 Aug 8. PubMed PMID: 28749667.7: Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci. 2017 Jul 19;24(1):47. doi: 10.1186/s12929-017-0355-7. Review. PubMed PMID: 28720101; PubMed Central PMCID: PMC5516350.8: Mullard A. BACE inhibitor bust in Alzheimer trial. Nat Rev Drug Discov. 2017 Mar 1;16(3):155. doi: 10.1038/nrd.2017.43. PubMed PMID: 28248932.9: Hawkes N. Merck ends trial of potential Alzheimer’s drug verubecestat. BMJ. 2017 Feb 15;356:j845. doi: 10.1136/bmj.j845. PubMed PMID: 28202490.10: Thaisrivongs DA, Miller SP, Molinaro C, Chen Q, Song ZJ, Tan L, Chen L, Chen W, Lekhal A, Pulicare SK, Xu Y. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer’s Disease. Org Lett. 2016 Nov 18;18(22):5780-5783. Epub 2016 Nov 4. PubMed PMID: 27934506.11: Scott JD, Li SW, Brunskill AP, Chen X, Cox K, Cumming JN, Forman M, Gilbert EJ, Hodgson RA, Hyde LA, Jiang Q, Iserloh U, Kazakevich I, Kuvelkar R, Mei H, Meredith J, Misiaszek J, Orth P, Rossiter LM, Slater M, Stone J, Strickland CO, Voigt JH, Wang G, Wang H, Wu Y, Greenlee WJ, Parker EM, Kennedy ME, Stamford AW. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease. J Med Chem. 2016 Dec 8;59(23):10435-10450. Epub 2016 Nov 18. PubMed PMID: 27933948.12: Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn HJ, Kuvelkar R, Li W, Mattson BA, Mei H, Palcza J, Scott JD, Tanen M, Troyer MD, Tseng JL, Stone JA, Parker EM, Forman MS. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients. Sci Transl Med. 2016 Nov 2;8(363):363ra150. PubMed PMID: 27807285.13: Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Lozupone M, Leo A, Sardone R, Gagliardi G, Lofano L, Creanza BC, Bisceglia P, Daniele A, Bellomo A, Greco A, Logroscino G. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients. Expert Opin Emerg Drugs. 2016 Dec;21(4):377-391. Epub 2016 Oct 6. Review. PubMed PMID: 27678025.14: Yan R. Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016 Jul 14;5:13. doi: 10.1186/s40035-016-0061-5. eCollection 2016. Review. PubMed PMID: 27418961; PubMed Central PMCID: PMC4944430.15: Evin G. Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors. BioDrugs. 2016 Jun;30(3):173-94. doi: 10.1007/s40259-016-0168-3. Review. PubMed PMID: 27023706.